News | Medical 3-D Printing | December 11, 2023

Mentice Enters Agreement to Acquire All Substantial Assets from Biomodex

Mentice AB, a world leader in simulation solutions for image guided interventional therapies, announced today that it has entered into an agreement to acquire all substantial assets from Paris-based company Biomodex

Getty Images


December 11, 2023 — Mentice AB, a world leader in simulation solutions for image guided interventional therapies, announced today that it has entered into an agreement to acquire all substantial assets from Paris-based company Biomodex for a purchase price of 200,000 EUR, following a decision by their board to dissolve operations. The global Biomodex business reached a total turnover of 2.2 million EUR in 2022.

The Acquisition

Biomodex specializes in biorealistic 3D printing and flow systems for interventional procedures, with a platform geared towards clinical use and patient-specific simulation. As part of the acquisition, Mentice will also retain key employees of Biomodex. “Biomodex is truly a quality product company, with experienced staff and a large and highly engaged customer base which is a testament to the value they bring to the market”, said Edward Fält, Chief Strategy Officer of Mentice. “Since its inception in 2015, Biomodex has invested over 12 million EUR in IP and R&D, leading to the development of several innovative products and technology advances which will be very synergistic to Mentice’s current portfolio. Thanks to a series of circumstances, we were able to acquire these assets under favorable terms and are now looking forward to taking the business to the next level under the umbrella of the global Mentice organization.”

The acquisition will further consolidate Mentice’s position as the leading provider of virtual, physical and decision-support simulation solutions for image-guided interventional therapies. The acquired assets will add new solutions for neurovascular and structural heart simulation as well as a rapid turn-around production process for direct printing of patient-specific anatomies.

Over the course of 2024, Mentice aims to focus on integrating the Biomodex staff, product lines and production into its existing business areas.

As an immediate step, Mentice will be reaching out to all Biomodex customers with more information on the combined offering and how to request product and sales support.

For more information: www.mentice.com


Related Content

News | Cardiovascular Business

July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing ...

Home July 29, 2024
Home
News | Cardiovascular Business

July 18, 2024 — Circle Cardiovascular Imaging, a developer of artificial intelligence (AI)-driven cardiovascular imaging ...

Home July 18, 2024
Home
News | Cardiovascular Business

July 15, 2024 — Guidehealth, an artificial intelligence (AI)-enabled healthcare services company, has announced a ...

Home July 15, 2024
Home
News | Cardiovascular Business

July 15, 2024 — Edwards Lifesciences announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an ...

Home July 15, 2024
Home
News | Cardiovascular Business

July 11, 2024 — Medical device company R3 Vascular Inc., developer of novel, best-in-class bioresorbable scaffolds for ...

Home July 11, 2024
Home
News | Cardiovascular Business

July 9, 2024 — Disparities in cardiovascular disease outcomes between urban and rural areas continue to widen, yet ...

Home July 09, 2024
Home
Feature | Cardiovascular Business

The DAIC team wishes you a safe and happy 4th of July!

Home July 04, 2024
Home
News | Cardiovascular Business

July 3, 2024 — Over the past decade, 342 cardiology clinics have been acquired by private equity firms, with over 94% of ...

Home July 03, 2024
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

From FDA approvals to new clinical trials, here is a look at DAIC's top-read content during the month of June: 1 ...

Home July 02, 2024
Home
News | Cardiovascular Business

July 1, 2024 — CVRx, Inc., a commercial-stage medical device company, announced three additions to its senior leadership ...

Home July 01, 2024
Home
Subscribe Now